CorMedix Inc. (CRMD) wird mit einem nachlaufenden KGV von gehandelt 3.5, erwartetes KGV von 9.2. Die nachlaufende Gewinnrendite beträgt 28.69%, erwartete Gewinnrendite 10.87%. PEG 0.36 (Peter Lynch unterbewertet ≤1,0). Die Graham-Zahl beträgt $15.47.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 82/100 mit 5/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | -2.4 | -0.20 | 3.26 | 259.21 | - |
| 2017 | -0.8 | 0.10 | -0.18 | 83.72 | - |
| 2018 | -4.3 | 0.09 | -0.64 | 267.38 | - |
| 2019 | -10.7 | 0.19 | -0.90 | 620.71 | - |
| 2020 | -9.6 | -0.73 | 4.80 | 887.07 | - |
| 2021 | -6.1 | 2.34 | 2.73 | 896.33 | - |
| 2022 | -5.7 | 4.28 | 3.08 | 2,589.59 | - |
| 2023 | -4.1 | -0.18 | 2.73 | 0.00 | - |
| 2024 | -26.6 | 0.40 | 5.63 | 10.97 | - |
| 2025 | 5.1 | -0.01 | 2.07 | 2.69 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $-3.25 | $224.11K | $-24.64M | -10996.5% |
| 2017 | $-2.99 | $329.33K | $-33.01M | -10023.4% |
| 2018 | $-1.51 | $429.8K | $-26.83M | -6242.4% |
| 2019 | $-0.68 | $283.27K | $-16.43M | -5801.3% |
| 2020 | $-0.77 | $239.23K | $-22.03M | -9207.7% |
| 2021 | $-0.75 | $190.94K | $-28.21M | -14774.7% |
| 2022 | $-0.74 | $65.41K | $-29.7M | -45409.9% |
| 2023 | $-0.91 | $0.00 | $-46.34M | - |
| 2024 | $-0.30 | $43.47M | $-17.93M | -41.2% |
| 2025 | $2.04 | $311.71M | $163.06M | 52.3% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $0.83 | $0.52 – $1.27 | $306.52M | $300.95M – $312.09M | 4 |
| 2027 | $0.53 | $0.02 – $0.98 | $290.09M | $281.47M – $298.71M | 4 |
| 2028 | $0.91 | $0.38 – $1.49 | $348.14M | $333.39M – $363.42M | 5 |
| 2029 | $1.34 | $1.27 – $1.42 | $423.59M | $405.64M – $442.18M | 1 |
| 2030 | $1.98 | $1.87 – $2.10 | $555.23M | $531.7M – $579.59M | 1 |
